AstraZeneca and CSL Adopt APAS Plate-Reading Units
The pharma giants are integrating automated technology to reduce human error and improve efficiency in sterile manufacturing.
Updated on Oct. 27, 2026 in Biotech
Live Poll
Do you trust automated technology more than human judgment for critical safety tasks?
AstraZeneca and CSL have publicly endorsed the APAS Independence system, an automated device designed to process and monitor agar plates. This technology utilizes code to identify organisms, replacing traditional human visual inspection in high-volume sterile facilities.
Why it matters
By automating quality control, these manufacturers aim to minimize human fatigue and operational error during the processing of thousands of samples. The shift allows for centralized inspection procedures, ultimately increasing throughput and reliability in sterile drug production.
The APAS Independence unit costs US$350,000 per device and automates the identification of organisms using code. AstraZeneca’s Macclesfield site currently processes 30,000 plates monthly, while CSL produces 1 million annual agar plates across its global plants.
The players
AstraZeneca
A British-Swedish multinational pharmaceutical and biotechnology company that focuses on discovery, development, and commercialization of prescription medicines.
CSL
An Australian biotechnology company that specializes in the research, development, and manufacture of plasma-derived and recombinant products.
Clever Culture Systems
A medical technology firm that develops automated hardware for microbiology laboratory workflows and plate-reading systems.
PSC Biotech
A life sciences consulting firm that provides professional services and technology solutions to the biotechnology and pharmaceutical industries.
The details
Clever Culture Systems has secured agreements with several industry leaders, including Pfizer, Novo Nordisk, and Bristol Myers Squibb. The rollout of these units reflects a broader adoption strategy targeting large-scale pharmaceutical manufacturers to modernize quality control workflows.
Timeline
Over the past two years, Clever Culture shifted its business strategy to prioritize large pharmaceutical companies.
October 27, 2026, marks the publication date of the reporting on these deployments.
The Tech Race
The transition to the APAS Independence system represents a significant shift from manual laboratory processes to fully automated microbial monitoring. This technology displaces traditional human inspection, establishing a new standard for precision in sterile pharmaceutical manufacturing.
For industry professionals, this transition reduces the time required for quality monitoring and minimizes risks associated with human error in manufacturing. Consumers may benefit indirectly through more efficient production timelines and enhanced safety oversight in sterile pharmaceutical supply chains.
The takeaway
Automated microbiology systems are increasingly becoming a standard investment for large-scale manufacturers seeking to eliminate human fatigue. Facilities looking to improve consistency should prioritize the integration of digital inspection tools to ensure reliable quality control.
Further reading
Learn more about the latest innovations in Biotech.
Live Poll
Do you trust automated technology more than human judgment for critical safety tasks?
